期刊文献+

磷酸二酯酶4在心脏疾病中作用的研究进展 被引量:2

Progress in role of phosphodiesterase 4 in heart diseases
下载PDF
导出
摘要 磷酸二酯酶4(PDE4)是细胞内特异性cAMP水解酶,PDE4可以通过调节心肌细胞内的cAMP水平,进而影响cAMP参与的一系列生理功能的调节。目前,PDE4在慢性阻塞性肺病和银屑癣等疾病中作用的研究较为广泛,该综述旨在介绍PDE4在实验动物和人心肌肥大、心衰和心律失常中作用的研究进展。首先,通过观察大鼠心肌肥大模型发现PDE4水平有明显降低,进而对人类病变的心脏进行研究,表明患病的心脏上PDE4A和PDE4D水解活性也有明显下降;其次,在人心衰的心肌细胞上,存在于心脏兰诺定2型受体/Ca2+复合体中的PDE4D3,水解cAMP的活性也有显著降低;最后,在β肾上腺素刺激下,离体人心肌细胞中PDE4受到抑制后,细胞内cAMP水平和L型Ca2+电流均增加,表明PDE4受抑制会增加心率失常的发生率。 Phosphodiesterase 4 (PDE4) is one of the main enzymes which are specific for the hydrolysis of cAMP. Meanwhile, PDE4 modulates cAMP level in cardiomyocytes, and then impacts on the regulation of a series of physiological functions. At present, the research on PDE4 is relatively wide in chronic obstructive pulmonary disease (COPD) and psoriasis, and this review aims to introduce research progress of the PDE4 in experimental animals and human myocardial hypertrophy, heart failure and arrhythmia. Firstly, by observing the myocardial hypertrophy in rats model, decrease was occurred in PDE4 level. Further, the pathological study of human heart showed that hydrolysis activities of PDE4A and PDE4D have obviously declined.Secondly, in the cardiac muscle cells of human heart failure, the activity of PDE4D3 obtained in the RyR2/Ca2+ complex was significantly reduced. Finally, with β-adrenergic stimulating, PDE4 was inhibited which resulted in the increase in intracellular cAMP levels and L-type Ca2+ current in human atrial myocyte. The study indicated that PDE4 inhibition will increase the incidence of arrhythmia.
出处 《中国药理学与毒理学杂志》 CAS CSCD 北大核心 2013年第6期1025-1028,共4页 Chinese Journal of Pharmacology and Toxicology
关键词 磷酸二酯酶4 cAMP信号通路 兰诺定2型受体 心脏疾病 phosphodiesterase 4 cAMP signaling ryanodine receptor 2 heart diseases
  • 相关文献

参考文献4

二级参考文献78

  • 1Bender AT,Beavo JA.Cyclic nucleotide phosphodiesterases:molecular regulation to clinical use.Pharmacol Rev,2006,58:488-520.
  • 2Richter W,Day P,Agrawal R,et al.Signaling from 1-and 2-adrenergic receptors is defined by differential interactions with PDE4.EMBO J,2008,27:384-393.
  • 3Mongillo M,Tocchetti G,Terrin A,et al.Compartmentalized phosphodiesterase-2 activity blunts β-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway.Circ Res,2006,98:226-234.
  • 4Torsten C,Alejandro GT,Marcus T,et al.Inotropy and L-type Ca^2+ current,activated by b1-and b2-adrenoceptors,are differently controlled by phosphodiesterases 3 and 4 in rat heart.Br J Pharmacol,2009,156:62-83.
  • 5Baillie GS.Compartmentalized signaling:spatial regulation of cAMP by the action of compartmentalized phosphodiesterases.FEBS J,2009,276:1790-1799.
  • 6Kumar P,Francis GS,Tang WH.Phosphodiesterase 5 inhibition in heart failure:mechanisms and clinical implications.Nat Rev Cardiol,2009,6:349-355.
  • 7Lugnier C.Cyclic nucleotide phosphodiesterase (PDE) superfamily:A new target for the development of specific therapeutic agents.Pharmacol Ther,2006,109:366-398.
  • 8Houslay MD,Baillie GS,Maurice DH.cAMP-Specific Phosphodiesterase-4 Enzymes in the Cardiovascular System:A Molecular Toolbox for Generating Compartmentalized cAMP Signaling.Circ.Res,2007,100:950-966.
  • 9Feil R,Feil S,Hofmann F.A heretical view on the role of NO and cGMP in vascular proliferative diseases.Trends Mol Med,2005,11:71-75.
  • 10Nagel DJ,Aizawa T,Jeon K,et al.Role of nuclear Ca~(2+)/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival.Circ Res,2006,98:777-784.

共引文献23

同被引文献49

  • 1展海霞,彭成.附子与干姜配伍对心衰大鼠血流动力学的影响[J].中药药理与临床,2006,22(1):42-44. 被引量:62
  • 2Mariani E,Monastero R,Mecocci P.Mild cognitive impairment:a systematic review[J].J Alzheimers Dis,2007,12(1):23-35.
  • 3Di Carlo A,Lamassa M,Baldereschi M,Inzitari M,Scafato E,Farchi G,et al.CIND and MCI in the Italian elderly:frequency,vascular risk factors,progression to dementia[J].Neurology,2007,68(22):1909-1916.
  • 4Noetzli M,Eap CB.Pharmacodynamic,pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease[J].Clin Pharmacokinet,2013,52(4):225-241.
  • 5Boomkamp SD,Mc Grath MA,Houslay MD,Barnett SC.Epac and the high affinity rolipram binding conformer of PDE4 modulate neurite outgrowth and myelination using an in vitro spinal cord injury model[J].Br J Pharmacol,2014,171(9):2385-2398.
  • 6Cameron RT,Coleman RG,Day JP,Yalla KC,Houslay MD,Adams DR,et al.Chemical informatics uncovers a new role for moexipril as a novel inhibitor of c AMP phosphodiesterase-4(PDE4)[J].Biochem Pharmacol,2013,85(9):1297-1305.
  • 7Zhang HT,O'Donnell JM.Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats[J].Psychopharmacology(Berl),2000,150(3):311-316.
  • 8Burgin AB,Magnusson OT,Singh J,Witte P,Staker BL,Bjornsson JM,et al.Design of phosphodiesterase 4D(PDE4D)allosteric modulators for enhancing cognition with improved safety[J].Nat Biotechnol,2010,28(1):63-70.
  • 9Zhang MZ,Zhou ZZ,Yuan X,Cheng YF,Bi BT,Gong MF,et al.Chlorbipram:a novel PDE4 inhibitor with improved safety as a potential antidepressant and cognitive enhancer[J].Eur J Pharmacol,2013,721(1-3):56-63.
  • 10Ahlstrm M,Pekkinen M,Huttunen M,LambergAllardt C.Cyclic nucleotide phosphodiesterases(PDEs)in human osteoblastic cells;the effect of PDE inhibition on c AMP accumulation[J].Cell Mol Biol Lett,2005,10(2):305-319.

引证文献2

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部